Drug intelligence / Profile preview

Proderma

Development stage: Preclinical
Lead developer: Biohellenika
Modality: Stem Cell Therapies → Cell Therapies, Hydrogel Systems → Drug Delivery Systems
Administration: Topical

Overview

**Proderma** is a preclinical regenerative wound-healing program coordinated by Biohellenika that is developing antimicrobial polymeric hydrogel skin-regeneration patches supplemented with extracellular-matrix components, bioactive peptides, and human adipose stromal cells. The patch is intended to support local tissue repair while providing inherent antimicrobial activity through material chemistry and surface topography, potentially avoiding the need for added antimicrobial drugs that could impair skin regeneration. ([biohellenika.gr](https://www.biohellenika.gr/profil/programmata/proderma))

Other names: Proderma

Beyond the preview

Go deeper on Proderma.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Proderma.

Explore the full profile